
    
      Group I (Highly Emetogenic Chemotherapy): Patients that accepted chemotherapy including
      Cisplatin≥50mg/m2, Carmustine>250mg/m2, Cyclophosphamide>1500mg/m2, Dacarbazine>60mg/m2,
      Doxorubicin>60mg/m2, Epirubicin>90mg/m2, IFO≥10g/m2 or AC program.

      Group II (Moderately Emetogenic Chemotherapy): Patients that accepted chemotherapy including
      any dose of Carboplatin, Daunorubicin, Oaliplatin, Irinotecan, or Doxorubicin<60mg/m2(not
      include liposomal doxorubicin), Epirubicin≤90mg/m2, Carmustine≤250mg/m2,
      Methotrexate≥250mg/m2, Cyclophosphamide≤1500mg/m2, Arabinoside>200mg/m2, IFO<10g/m2,
      Cisplatin≥50mg/m2.

      Total subjects: 1000, single dose of palonosetron group of 500 patients, repeated doses of
      palonosetron group of 500 patients. According to the study subjects receiving highly
      emetogenic chemotherapy or moderately emetogenic chemotherapy, subjects are stratified
      randomize.
    
  